<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="review-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Transl Androl Urol</journal-id><journal-id journal-id-type="iso-abbrev">Transl Androl Urol</journal-id><journal-id journal-id-type="pmc-domain-id">2883</journal-id><journal-id journal-id-type="pmc-domain">trandur</journal-id><journal-id journal-id-type="publisher-id">TAU</journal-id><journal-title-group><journal-title>Translational Andrology and Urology</journal-title></journal-title-group><issn pub-type="epub">2223-4691</issn><publisher><publisher-name>AME Publications</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC10080345</article-id><article-id pub-id-type="pmcid-ver">PMC10080345.1</article-id><article-id pub-id-type="pmcaid">10080345</article-id><article-id pub-id-type="pmcaiid">10080345</article-id><article-id pub-id-type="pmid">37032753</article-id><article-id pub-id-type="doi">10.21037/tau-22-641</article-id><article-id pub-id-type="publisher-id">tau-12-03-497</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Review Article</subject></subj-group></article-categories><title-group><article-title>The utility of clinical registries for guiding clinical practice in upper tract urothelial cancer: a narrative review</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Kealey</surname><given-names initials="J">Joshua</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="afn2" ref-type="author-notes">^</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Snider</surname><given-names initials="R">Ruth</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Hayne</surname><given-names initials="D">Dickon</given-names></name><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Davis</surname><given-names initials="ID">Ian D.</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff4" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Sengupta</surname><given-names initials="S">Shomik</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref></contrib><aff id="aff1"><label>1</label><institution content-type="dept">Eastern Health Clinical School</institution>, <institution>Monash University</institution>, <addr-line>Melbourne</addr-line>, <country country="au">Australia</country>;</aff><aff id="aff2"><label>2</label><institution>Urology Department, Eastern Health</institution>, <addr-line>Melbourne</addr-line>, <country country="au">Australia</country>;</aff><aff id="aff3"><label>3</label><institution content-type="dept">UWA Medical School</institution>, <institution>University of Western Australia</institution>, <addr-line>Perth</addr-line>, <country country="au">Australia</country>;</aff><aff id="aff4"><label>4</label><institution>Oncology Department, Eastern Health</institution>, <addr-line>Melbourne</addr-line>, <country country="au">Australia</country></aff></contrib-group><author-notes><fn id="afn1"><p><italic toggle="yes">Contributions:</italic> (I) Conception and design: J Kealey, D Hayne, S Sengupta, ID Davis; (II) Administrative support: R Snider; (III) Provision of study materials or patients: All authors; (IV) Collection and assembly of data: J Kealey, R Snider; (V) Data analysis and interpretation: J Kealey, R Snider; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors.</p></fn><corresp id="cor1"><italic toggle="yes">Correspondence to:</italic> Professor Shomik Sengupta. Level 2, 5 Arnold St., Box Hill, Melbourne, VIC 3128, Australia. Email: <email xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="shomik.sengupta@monash.edu">shomik.sengupta@monash.edu</email>.</corresp><fn id="afn2"><label>^</label><p>ORCID: 0000-0001-7387-5084.</p></fn></author-notes><pub-date pub-type="epub"><day>16</day><month>3</month><year>2023</year></pub-date><pub-date pub-type="ppub"><day>31</day><month>3</month><year>2023</year></pub-date><volume>12</volume><issue>3</issue><issue-id pub-id-type="pmc-issue-id">433014</issue-id><fpage>497</fpage><lpage>507</lpage><history><date date-type="received"><day>30</day><month>9</month><year>2022</year></date><date date-type="accepted"><day>14</day><month>2</month><year>2023</year></date></history><pub-history><event event-type="pmc-release"><date><day>31</day><month>03</month><year>2023</year></date></event><event event-type="pmc-live"><date><day>08</day><month>04</month><year>2023</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-09-15 13:25:29.857"><day>15</day><month>09</month><year>2024</year></date></event></pub-history><permissions><copyright-statement>2023 Translational Andrology and Urology. All rights reserved.</copyright-statement><copyright-year>2023</copyright-year><copyright-holder>Translational Andrology and Urology.</copyright-holder><license><ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p><italic toggle="yes">Open Access Statement:</italic> This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">https://creativecommons.org/licenses/by-nc-nd/4.0</ext-link>.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="tau-12-03-497.pdf"/><related-article xmlns:xlink="http://www.w3.org/1999/xlink" related-article-type="commentary" xml:lang="en" xlink:title="editorial" journal-id="Transl Androl Urol" journal-id-type="nlm-ta" ext-link-type="pmc" xlink:href="PMC10406535"><article-title>Clinical registries in upper tract urothelial carcinoma: commitment to collaboration</article-title><volume>12</volume><issue>7</issue><date><day>19</day><month>6</month><year>2023</year></date><fpage>1043</fpage><lpage>1044</lpage><source>Translational Andrology and Urology</source><pub-id pub-id-type="doi">10.21037/tau-23-232</pub-id><pub-id pub-id-type="pmcid">PMC10406535</pub-id><pub-id pub-id-type="pmid">37554523</pub-id></related-article><abstract><sec><title>Background and Objective</title><p>Upper tract urothelial cancer (UTUC) lacks high-quality evidence to appraise current patterns of presentation, diagnosis, treatment and outcomes as a result of disease rarity and patient heterogeneity. Registries may overcome many of the challenges making clinical trials challenging in UTUC and provide answers to many of the clinical questions that afflict UTUC management. In this narrative review we aim to summarise the design of registries that have contributed to the UTUC literature, discuss their strengths and limitations and the future directions of registries in UTUC.</p></sec><sec><title>Methods</title><p>Two independent reviewers conducted a search of the OVID MEDLINE database from July 2002&#8211;July 2022. Included articles were required to be published in peer reviewed journals and use registry-based methodology to report on UTUC. Search was limited by MeSH and key words and was limited to the English language.</p></sec><sec><title>Key Content and Findings</title><p>One hundred and forty-four articles were identified and included as reporting on UTUC from a registry-based methodology. Articles utilising registry-based data have substantially increased over the study period with the majority of articles arising from large generalised cancer databases in North America. There has been an increase in UTUC-specific registries in the previous five years that have offered the most granular, complete analysis and these will continue to report in the coming years. The majority of published data assessed epidemiological factors and compared outcomes of treatment modalities with a small proportion of articles focusing on prognostic nomograms and quality of life. Larger cancer registries that contribute the majority of the published analysis are likely subject to significant selection bias when comparing cohorts for treatment analysis and the need for prospective UTUC specific registries is apparent. Future directions include the potential for registry-based randomised controlled trials (RCTs) and clinical quality registries (CQR) that have the ability to change practice and improve care.</p></sec><sec><title>Conclusions</title><p>The utilisation of registry-based methodology for analysis in UTUC has increased substantially over the last 20 years. In addition to the utilisation of large cancer registries, the creation of UTUC specific registries is likely to contribute the most granular, translatable data in diagnosis and management.</p></sec></abstract><kwd-group kwd-group-type="author"><title>Keywords: </title><kwd>Registry</kwd><kwd>upper tract urothelial carcinoma</kwd><kwd>transitional cell carcinoma</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro"><title>Introduction</title><p>Upper tract urothelial cancer (UTUC) arises from the urothelial lining of the kidney or ureter and accounts for approximately 5&#8211;10% of all urothelial cancer (UC) (<xref rid="r1" ref-type="bibr">1</xref>). Whilst incidence of UTUC remains low at 1&#8211;3 cases/100,000 people/year, it is rising in many nations around the world (<xref rid="r2" ref-type="bibr">2</xref>). There are histological similarities between UTUC and bladder UC however the presentation, diagnosis, treatment and outcomes differ significantly. Patients diagnosed with UTUC are likely to be older with more comorbidities and are presenting with more invasive disease (<xref rid="r3" ref-type="bibr">3</xref>). This in combination with a low incidence often makes recruitment into clinical trials challenging and costly. For this reason, much of the understanding of UTUC is extrapolated from bladder UC or from systematic reviews that often rely on low-level evidence with many clinical questions remaining unanswered.</p><p>Registries are structured data repositories that systematically collect and store health related data (<xref rid="r4" ref-type="bibr">4</xref>). Registries collect observational data about a specific exposure, disease, treatment or healthcare resource (<xref rid="r5" ref-type="bibr">5</xref>). In general health registries are designed to be broad and have few if any exclusion criteria in order to quickly capture large patient cohorts and relay a real-world experience of patient care. Health related registries come in several different forms with different purposes and requirements.</p><p>Disease- or condition-specific registries are the most common form of registry and collect information on patients diagnosed with that disease in a specific setting such as a hospital or outpatient setting (<xref rid="r6" ref-type="bibr">6</xref>). These registries provide varied levels of epidemiological, diagnostic, treatment and outcome data. Common examples are cancer registries or rare-disease registries. These are often maintained at a state or national level and many countries around the world maintain comprehensive repositories that can be accessed for clinical research (<xref rid="r7" ref-type="bibr">7</xref>).</p><p>Drug or medical device registries are designed to monitor the safety and efficacy of medication or devices utilised in healthcare. Their main purpose is to monitor long-term real-world outcomes of medical devices and facilitate recalls where required (<xref rid="r8" ref-type="bibr">8</xref>). They are usually maintained by the medical device company, may not be publicly accessible and often collect a very narrow range of data.</p><p>Clinical quality registries (CQR) are similar to disease or condition specific registries however collect data to evaluate defined outcomes at predetermined intervals. Outcomes are then benchmarked against set standards, either local or international, and reported in a timely fashion to healthcare providers (<xref rid="r9" ref-type="bibr">9</xref>). Commonly assessed predefined outcomes include pre-operative waiting times, surgical margin status and 30-day post-operative complication rates. Whilst observational data analysis and contribution to the literature is provided the extra utility is provided in the ability to identify variations in the process and outcomes of care and adherence to evidence based guidelines. This information can then be reported back to providers and quality improvement processes undertaken with the eventual outcome of improving and standardising patient care. Interest in CQR has increased substantially in recent years as safety and quality of health provision continues to grow as a pillar of healthcare delivery (<xref rid="r10" ref-type="bibr">10</xref>).</p><p>In this narrative review, we aim to summarise the design of recent and current registries that have contributed to the UTUC literature, discuss their strengths and limitations and the future directions of registries in UTUC in the hope of improving awareness and collaboration with such registries. We present the following article in accordance with the Narrative Review reporting checklist (available at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://tau.amegroups.com/article/view/10.21037/tau-22-641/rc" ext-link-type="uri">https://tau.amegroups.com/article/view/10.21037/tau-22-641/rc</ext-link>).</p></sec><sec sec-type="methods"><title>Methods</title><p>Two independent reviewers conducted a search of the OVID MEDLINE database from July 2002&#8211;July 2022. A third reviewer was utilised only if a there was not consensus regarding articles to be included. The review was conducted between July 2022 and August 2022. Articles included were required to report on UTUC with an observational study design arising from a registry. Single-institutional or multi-institutional retrospective data that did not arise from a registry design was excluded from analysis as it did not meet the definition of a registry. Articles were required to be published in journals and abstracts from meetings were excluded. Where discrepancies on articles to be included arose a third independent reviewer was utilised. Search was limited by MeSH and Key words and was limited to the English language. The search strategy utilised is included in <xref rid="t1" ref-type="table"><italic toggle="yes">Table 1</italic></xref>.</p><table-wrap position="float" id="t1" orientation="portrait"><label>Table 1</label><caption><title>The search strategy summary</title></caption><table frame="hsides" rules="groups"><col width="28.74%" span="1"/><col width="71.26%" span="1"/><thead><tr><th valign="middle" align="left" scope="col" rowspan="1" colspan="1">Items</th><th valign="middle" align="left" scope="col" rowspan="1" colspan="1">Specification</th></tr></thead><tbody><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Date of search </td><td valign="top" align="left" rowspan="1" colspan="1">01/07/2022</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Databases and other sources searched</td><td valign="top" align="left" rowspan="1" colspan="1">OVID and MEDLINE</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Search terms used </td><td valign="top" align="left" rowspan="1" colspan="1">Free</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Registry</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Database</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Register</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Regist</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Upper Tract Urothelial Carcinoma</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Upper Tract Transitional Cell carcinoma</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">UTUC</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Urothelial Cancer</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Upper tract urothelial cancer</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Carcinoma, transitional cell</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Carcinomas, transitional cell</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Cell carcinoma, transitional</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Cell carcinomas, transitional</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Transitional cell carcinoma</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Transitional cell carcinomas</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Cancer, ureteral</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Cancer of ureter</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Cancer of the ureter</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Cancers, ureteral</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Neoplasm, ureteral</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Neoplasms, ureteral</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Neoplasms of ureter</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Ureter cancer</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Ureter, cancer of</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Ureter cancers</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Ureter neoplasm</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Ureter neoplasms</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Ureteral cancer</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Ureteral cancers</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Ureteral neoplasm</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Ureteral neoplasms</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Kidney neoplasm</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">MeSH</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Carcinoma, Transitional Cell</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Ureteral neoplasm</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Kidney neoplasm</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Registries</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Database management systems</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Timeframe</td><td valign="top" align="left" rowspan="1" colspan="1">1<sup>st</sup> July, 2002&#8211;1<sup>st</sup> July, 2022 </td></tr><tr><td rowspan="2" valign="top" align="left" scope="row" colspan="1">Inclusion and exclusion criteria </td><td valign="top" align="left" rowspan="1" colspan="1">Inclusion: registry based observational cohort study, English language, full text available </td></tr><tr><td valign="top" colspan="1" align="left" scope="col" rowspan="1">Exclusion: single or multicentre once-off data collection that was not in a registry based format. Not published in a medical journal</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Selection process </td><td valign="top" align="left" rowspan="1" colspan="1">Two independent reviewers separately reviewed all articles, and 3<sup>rd</sup> reviewer if discrepancy</td></tr></tbody></table></table-wrap></sec><sec sec-type="results"><title>Results</title><p>A total of 516 articles were identified using the search method outlined, of which 327 were identified for abstract or full text review. Of these articles 144 were included as utilising registry-based data as the basis of the article. The results are grouped and summarised below.</p><sec><title>Major North American general registries</title><sec><title>Surveillance, epidemiology and end results (SEER) program</title><p>The SEER program collects and analyses data from population-based cancer registries that covers approximately 48% of the population in the United States (<xref rid="r11" ref-type="bibr">11</xref>). It is facilitated by the National Cancer Institute and routinely collects a wide array of data on numerous tumour types including UTUC. Rather than a single centralised data collection program SEER combines approximately 30 state and regional based cancer registries and allows access to collated data for research purposes. Data available is from 1975 until current and includes demographics, tumour type, tumour stage, initial treatments and some outcome data (<xref rid="r12" ref-type="bibr">12</xref>).</p><p>The SEER program is the registry with the highest number of published articles on UTUC, with 48 publications to date. Publications utilising the SEER project have increased substantially over the study time period with approximately 75% of publications arising in the last 5 years. Articles describing incidence, demographics, presentation and diagnosis of UTUC were most common accounting for 23/48 articles, whilst comparison of treatments accounted for 19/48 articles. Since 2020, several articles utilising prognostic scoring systems have also been published using SEER data.</p></sec><sec><title>National Cancer Database (NCDB)</title><p>The NCDB is a registry of cancer patients treated at institutions accredited by the American Cancer Society and is a joint registry with the American College of Surgeons (<xref rid="r13" ref-type="bibr">13</xref>). The NCDB covers approximately 70% of the population of the United States of America and provides in depth demographic data as well as institutional data including institution volume. As data collection only occurs in hospitalised patients rather than population based the generalisability of these results may be more challenging (<xref rid="r14" ref-type="bibr">14</xref>). Data was made available to accredited institutions from 2013 and is republished annually.</p><p>NCDB was the second most commonly utilised registry in UTUC publications in the study period with 28 published articles. The vast majority of articles were published after 2017 with a steady increase in publications each year. Articles focusing on comparative treatment outcomes were the most common accounting for 18/28 articles, followed by incidence, demographics, presentation and diagnosis 9/28. In comparison to SEER only one article was published utilising the NCDB for a prognostic scoring system.</p></sec><sec><title>Other North American registries</title><p>The National Surgical Quality Improvement Program (NSQIP) database is the only CQR that was identified to contribute to the UTUC literature. NSQIP provides detailed patient and outcome data for major operations including nephroureterectomy and includes institution and clinician feedback and benchmarking (<xref rid="r15" ref-type="bibr">15</xref>). Patient outcomes are tracked up to 30 days and hence publications in UTUC focus on the early post-operative period only (<xref rid="r16" ref-type="bibr">16</xref>,<xref rid="r17" ref-type="bibr">17</xref>). Follow-up is active and includes screening hospital readmissions, medical records, private surgeons&#8217; rooms and direct patient follow-up. Data provided is collected by trained Surgical Clinical Reviewers and analysis is robust and risk-adjusted for patient health and surgical complexity to minimise bias. Over 195 risk-adjusted models are provided to clinicians and institutions and benchmarking occurs via rankings and gives clear indication of an institution&#8217;s performance and areas of excellence or poor performance. NSQIP has now expanded outside of North America and has program sites in Australia that are utilising the same registry format to analyse and improve outcomes although data has not been published.</p><p>Several other North American registries have utilised claims-based data to publish articles on UTUC although the number of published articles is low (<xref rid="r18" ref-type="bibr">18</xref>,<xref rid="r19" ref-type="bibr">19</xref>). The majority of these registries include routine data collected for health-related billing practices with analyses for the medical literature a secondary function. Other data from hospital admission registries that are non-specific to cancer or UTUC have also been utilised to assess demographic data of those presenting with UTUC (<xref rid="r20" ref-type="bibr">20</xref>).</p></sec></sec><sec><title>International general registries</title><p>Other large nonspecific cancer registries have been utilised internationally to contribute to the UTUC literature. Scandinavian countries including Denmark (<xref rid="r21" ref-type="bibr">21</xref>,<xref rid="r22" ref-type="bibr">22</xref>), Norway (<xref rid="r2" ref-type="bibr">2</xref>), Iceland (<xref rid="r23" ref-type="bibr">23</xref>), and The Netherlands (<xref rid="r24" ref-type="bibr">24</xref>) have all contributed to the UTUC literature utilising large cancer and admission based registries. Other European nations have also utilised registry based data to contribute to their understanding of UTUC including Spain (<xref rid="r25" ref-type="bibr">25</xref>), Croatia (<xref rid="r26" ref-type="bibr">26</xref>), and The United Kingdom via the National Cancer Repository (<xref rid="r27" ref-type="bibr">27</xref>). There have also been joint efforts to understand rare cancers such as UTUC in multinational collaborations (<xref rid="r28" ref-type="bibr">28</xref>). In the Asia-Pacific region/countries including Japan (<xref rid="r29" ref-type="bibr">29</xref>,<xref rid="r30" ref-type="bibr">30</xref>), Taiwan (<xref rid="r31" ref-type="bibr">31</xref>), and Australia (<xref rid="r32" ref-type="bibr">32</xref>) have utilised broad cancer registries and admissions data to publish UTUC articles. Over 80% of articles appraised from these registries focused on local incidence, demographics, presentation and diagnosis of UTUC with the remaining 20% relating to comparative treatment outcomes.</p></sec><sec><title>Urology specific registries</title><p>The British Association of Urological Surgery (BAUS) registry assesses complications and outcomes up to 30 days post-surgery and has been utilised to assess nephroureterectomy outcomes in the short term (<xref rid="r33" ref-type="bibr">33</xref>). It provided a comparatively large patient sample of 863 patients and 119 centres over a 1-year period with detailed analysis of final pathology, operative technique, complications and short-term outcomes after surgery for UTUC. Whilst the BAUS registry is not specific to UTUC it does provide a deeper level of analysis for the operative treatment of UTUC than non-specific registries. Further research questions of the BAUS registry aim to address outcomes of varying techniques of the managing the distal ureter at nephroureterectomy with at least 2 years of follow-up.</p><p>The Retrospective International Database of Invasive/Advanced Cancer of the Urothelium (RISC) database is a retrospective international multicentre database that collected data on patients with advanced UC including UTUC. Data collection spanned from 2006&#8211;2011. There have been several published papers including predictive nomograms and descriptions of chemotherapy utilisation that include patients with UTUC in a broad base of UC patients (<xref rid="r34" ref-type="bibr">34</xref>-<xref rid="r37" ref-type="bibr">37</xref>).</p><p>The Japanese Urological Association Multi-Institutional National Registry was an observational cohort study including 348 institutions that took place in 2005. Data was retrospectively collected for patients diagnosed with UTUC and renal cell cancer; 1,500 UTUC patients were included in the registry which included detailed data regarding operative technique and outcomes in addition to demographic data. Several published articles including comparisons of laparoscopic <italic toggle="yes">vs.</italic> open technique and outcomes and prognostic factors for recurrent disease were published (<xref rid="r38" ref-type="bibr">38</xref>-<xref rid="r41" ref-type="bibr">41</xref>). There have been no further publications or data collection reported.</p></sec><sec><title>UTUC specific registries</title><p>Several national, multicentre UTUC registries have been created in the last 20 years in an attempt to understand current practice and outcomes. The French National Collaborative Database of Upper Urinary Tract Urothelial Cancer was a multi-institutional, retrospective cohort study including 20 centres from 1995&#8211;2010 that recorded approximately 500 patients who underwent curative intent treatment for UTUC. Published results included comparisons of oncological outcomes of radical segmental ureterectomy <italic toggle="yes">vs.</italic> nephroureterectomy, adjuvant chemotherapy, synchronous bladder tumours during nephroureterectomy and several online nomograms and prognostic tools (<xref rid="r42" ref-type="bibr">42</xref>-<xref rid="r47" ref-type="bibr">47</xref>). The registry does not appear to have continued after 2010 and no further studies have been published since 2014.</p><p>The Taiwan Upper Tract Urothelial Cancer Registry is a multicentre, observational registry that collects and analyses data on patients treated for UTUC. It includes 95 surgeons at 12 centres who retrospectively registered patients from 1988&#8211;2021. In total 3,333 patients underwent nephroureterectomy in the 33-year study period and were included. Published results have included adverse prognostic factors for survival post nephroureterectomy and a comparison of endoscopic treatment vs radical nephroureterectomy for patients with tumours T2 or lower (<xref rid="r48" ref-type="bibr">48</xref>-<xref rid="r50" ref-type="bibr">50</xref>). The registry remains open and continues to enrol patients with likely further publications.</p><p>There has been a recent push to obtain an understanding of UTUC at an international level that will allow comparison and improve applicability of results. The Clinical Research Office of the Endourology Society (CROES)-UTUC registry is the largest and most complete UTUC registry published. The CROES-UTUC registry is an international, multicentre, prospective, observational cohort study with an enrolment period of 5 years (November 2014&#8211;November 2019) and a follow-up period of 5 years post inclusion (<xref rid="r51" ref-type="bibr">51</xref>). Any patient undergoing a diagnostic or therapeutic procedure for UTUC at participating centres was included. The primary objective is to describe the patterns of presentation, diagnosis, treatment and outcomes of those with UTUC. Further objectives include an assessment of evidence-based guideline adherence, post-operative complications, recurrence rates and mechanisms and comparison of individual treatment outcomes. Data capture is broad and includes demographic data, risk factors, treatments and complications as well as survival data at 1, 3 and 5 years after diagnosis. The registry aimed to recruit 3,000 patients in the 5-year study period.</p><p>Enrolment into CROES-UTUC began in 2014 and closed in 2019 with a small pool of published results to date. In total 2,451 patients were enrolled across 125 centres in 37 countries. A single study analysing flexible fibre optic <italic toggle="yes">vs</italic> digital ureteroscopy and enhanced <italic toggle="yes">vs.</italic> unenhanced imaging in the diagnosis and treatment of UTUC has been published with 5-year survival rates to date of writing (<xref rid="r52" ref-type="bibr">52</xref>). This study failed to find a significant difference in overall survival or disease-free survival between enhanced and unenhanced imaging techniques. Further analysis of mid and long-term are expected from the CROES-UTUC registry in the near future (<xref rid="r51" ref-type="bibr">51</xref>).</p><p>The Robotic Surgery for Upper Tract Urothelial Cancer Study (ROBUUST) is an international, multicentre, retrospective cohort study that systematically collects data on patients undergoing minimally invasive (robotic or laparoscopic) surgery for UTUC. The study includes 17 institutions around the world including the United States of America, China, Belgium, Italy and Korea and utilises a purpose-built registry for enrolment between February 2006 and March 2020. As of 2021, 877 patients had been enrolled into the registry. Research outputs from the registry have shown a significant intravesical recurrence rate of approximately 25% post-nephroureterectomy with risk factors including previous ureteroscopy, hypertension, positive surgical margin and transurethral bladder cuff resection (<xref rid="r53" ref-type="bibr">53</xref>). Results also failed to show a survival benefit from lymph node dissection at time of nephroureterectomy for UTUC (<xref rid="r54" ref-type="bibr">54</xref>). Most recently the ROBUUST data was utilised to create a pre-operative nomogram to predict renal insufficiency for cisplatin-based adjuvant therapy post minimally invasive nephroureterectomy (<xref rid="r55" ref-type="bibr">55</xref>). Further research outputs are expected in 2023 from the registry that is continuing to enrol.</p></sec></sec><sec sec-type="discussion"><title>Discussion</title><sec><title>How is registry data utilised in UTUC research?</title><p>In total 144 articles were identified as utilising registry-based data to contribute to the understanding of UTUC from a wide variety of study designs and geographical locations (<xref rid="t2" ref-type="table"><italic toggle="yes">Table 2</italic></xref>). Individual treatments and their outcomes were the most commonly evaluated aspects of UTUC followed by articles focusing on epidemiology, presentation or diagnosis of UTUC (<xref rid="t3" ref-type="table"><italic toggle="yes">Table 3</italic></xref>). Articles relating to risk calculators and prognostic nomograms and quality of life were far less common and accounted for approximately 8% of the published literature.</p><table-wrap position="float" id="t2" orientation="portrait"><label>Table 2</label><caption><title>Origin of published articles including registry type and geographical distribution</title></caption><table frame="hsides" rules="groups"><col width="71.91%" span="1"/><col width="28.09%" span="1"/><thead><tr><th valign="middle" align="left" scope="col" rowspan="1" colspan="1">Registry type</th><th valign="middle" align="center" scope="col" rowspan="1" colspan="1">Publications</th></tr></thead><tbody><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Total, n</td><td valign="top" align="center" rowspan="1" colspan="1">144</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Large generalised cancer or admission based, n/n [%]</td><td valign="top" align="center" rowspan="1" colspan="1">117/144 [81]</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">&#160;&#160;&#160;SEER</td><td valign="top" align="center" rowspan="1" colspan="1">48/117 [41]</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">&#160;&#160;&#160;NCDB</td><td valign="top" align="center" rowspan="1" colspan="1">28/117 [24]</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">&#160;&#160;&#160;Other North American</td><td valign="top" align="center" rowspan="1" colspan="1">10/117 [8]</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">&#160;&#160;&#160;Scandinavian</td><td valign="top" align="center" rowspan="1" colspan="1">10/117 [8]</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">&#160;&#160;&#160;Other European</td><td valign="top" align="center" rowspan="1" colspan="1">6/117 [5]</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">&#160;&#160;&#160;Asia-Pacific</td><td valign="top" align="center" rowspan="1" colspan="1">15/117 [13]</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Clinical quality, n [%] </td><td valign="top" align="center" rowspan="1" colspan="1">1 [1]</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Urology specific, n [%]</td><td valign="top" align="center" rowspan="1" colspan="1">11 [8]</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">UTUC specific, n [%] </td><td valign="top" align="center" rowspan="1" colspan="1">15 [10]</td></tr></tbody></table><table-wrap-foot><p>SEER, Surveillance, Epidemiology and End Results; NCDB, National Cancer Database; UTUC, upper tract urothelial cancer.</p></table-wrap-foot></table-wrap><table-wrap position="float" id="t3" orientation="portrait"><label>Table 3</label><caption><title>Focus of the research question for publications utilising registry-based data in UTUC research</title></caption><table frame="hsides" rules="groups"><col width="70.24%" span="1"/><col width="29.76%" span="1"/><thead><tr><th valign="middle" align="left" scope="col" rowspan="1" colspan="1">Research purpose focus</th><th valign="middle" align="center" scope="col" rowspan="1" colspan="1">Number</th></tr></thead><tbody><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Epidemiology &amp; diagnosis</td><td valign="top" align="center" rowspan="1" colspan="1">43</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">&#160;&#160;&#160;Incidence</td><td valign="top" align="center" rowspan="1" colspan="1">10</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">&#160;&#160;&#160;Risk factors &amp; presentation</td><td valign="top" align="center" rowspan="1" colspan="1">25</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">&#160;&#160;&#160;Diagnosis</td><td valign="top" align="center" rowspan="1" colspan="1">8</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Treatment &amp; outcomes</td><td valign="top" align="center" rowspan="1" colspan="1">89</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">&#160;&#160;&#160;Oncological outcomes</td><td valign="top" align="center" rowspan="1" colspan="1">32</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">&#160;&#160;&#160;Survival outcomes</td><td valign="top" align="center" rowspan="1" colspan="1">45</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">&#160;&#160;&#160;Treatment strategies</td><td valign="top" align="center" rowspan="1" colspan="1">8</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">&#160;&#160;&#160;Safety</td><td valign="top" align="center" rowspan="1" colspan="1">4</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Renal function assessment</td><td valign="top" align="center" rowspan="1" colspan="1">1</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Cost-assessment</td><td valign="top" align="center" rowspan="1" colspan="1">2</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Prognostic nomograms</td><td valign="top" align="center" rowspan="1" colspan="1">8</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Quality of life</td><td valign="top" align="center" rowspan="1" colspan="1">1</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Total</td><td valign="top" align="center" rowspan="1" colspan="1">144</td></tr></tbody></table><table-wrap-foot><p>UTUC, upper tract urothelial cancer.</p></table-wrap-foot></table-wrap><p>Registry based publications have increased substantially within the study period with approximately 70% of articles published in the last 5 years of the 20-year study period (<xref rid="f1" ref-type="fig"><italic toggle="yes">Figure 1</italic></xref>). This increase in publications in the last 5 years is likely related to an increase in registry creation, but also an increase in the understanding of the utility of registries as more outputs are seen in leading publications. Data from registries in some cases have also become more easily accessible to researchers, such as the NCDB which in 2012 allowed access to the registry to involved institutions with the first UTUC publication from this source in 2017. Since that initial publications there have been at least 27 articles published as researchers and clinicians have come to understand the dataset and its potential utility.</p><fig position="float" id="f1" fig-type="figure" orientation="portrait"><label>Figure 1</label><caption><p>Number of publications per year utilising registry-based methodology in UTUC. UTUC, upper tract urothelial cancer.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="tau-12-03-497-f1.jpg"/></fig></sec><sec><title>Benefits of registry use in UTUC</title><p>The most potent strength of registries in UTUC is the sheer volume of patients that are able to be recruited and followed up in a registry-based study format. CROES-UTUC registry has been able to recruit over 2,000 patients in a 5-year period and have excellent follow-up rates to 5 years (<xref rid="r52" ref-type="bibr">52</xref>), whilst NCDB publications have been able to analyse up to 8,000 patients in some instances (<xref rid="r56" ref-type="bibr">56</xref>). This is in stark contrast to randomised control trials that can often be underpowered and require recruitment over many years and centres to enrol small patient samples. Comparative cost compared to randomised controlled trials (RCTs) is another significant benefit that allows for economical recruitment of such large patient numbers (<xref rid="r57" ref-type="bibr">57</xref>). Registry based data collection can occur at a fraction of the cost of running clinical trials, which is especially true in rare malignancies such as UTUC, where multiple sites recruiting only small patient numbers are required to gain a sufficient sample size.</p></sec><sec><title>Limitations of registry-based data use</title><p>There are several limitations of large databases when analysing UTUC. Registry-based data may be more prone to selection bias due to an inability to randomise patients. This allows for inherent and often unmeasured variables to impact on the various treatments that individual patients receive. Non-specific datasets, such as SEER and NCDB, may be more prone to this given the non-specific nature of the data collected (<xref rid="r12" ref-type="bibr">12</xref>). Selection bias can lead to a comparison of interventions occurring in very different patient cohorts whose differing outcomes may not be solely attributable to the treatment being utilised. Non-participation bias will also be present in these studies as treatment for UTUC is an inclusion criterion in nearly all utilised registries, therefore excluding those that never receive treatment.</p><p>The quality of the registry is reliant on the data that is input into the registry. Data quality is nearly impossible to appraise however and occurred in very heterogenous ways depending on the registry in this review (<xref rid="r58" ref-type="bibr">58</xref>). In larger, non-specific registers much of this data was either automated or entered by researchers not involved in the care of the patient. In contrast most of the UTUC specific and smaller registries utilised the treating clinician or health team to input data. This may allow for more granular detailed data, but also allows for bias in the data that is collected and analysed. Specifically trained expert data collectors are the gold-standard and occurred in only a small proportion of the included registries. Incomplete data is a common problem no matter the collection method, and inadequate follow-up or documentation may mean that important events and outcomes, such as adverse events, are missed and do not contribute to analysis. Data time points are often dictated by the patient&#8217;s interactions with the health system, rather than at set intervals as is the case with RCTs, and hence there may be further lack of capture of outcomes of interest.</p><p>Protocol publication occurred in only a small pool of the UTUC specific registries. Protocol publication ensures transparency in the research, minimises publication bias and prevents selective reporting of outcomes. Assessment of registry quality is more challenging than RCT critical appraisal and whilst some published assessment tools have been published these have not been validated or widely adopted (<xref rid="r59" ref-type="bibr">59</xref>). Publication of the registry protocol and objectives allows for improved peer-review and validity of results and should be part of best-practice in registry creation.</p></sec></sec><sec sec-type="other1"><title>Future directions</title><p>CQR have the ability to provide feedback and benchmarking for clinicians, hospitals and organisations and are an increasingly prevalent quality improvement tool (<xref rid="r60" ref-type="bibr">60</xref>). Improvement in evidence-based guideline adherence, improved care availability and overall improvement in the quality of care are major benefits of CQR as is a reduction in the cost of care (<xref rid="r10" ref-type="bibr">10</xref>). Such registries have had significant success in other urological malignancies such as prostate cancer and have the ability to cover large cohorts (<xref rid="r61" ref-type="bibr">61</xref>). The NSQIP was the only identified example of a CQR in this narrative review and provides detailed clinician feedback up to 30 days post-operatively. There is however a large scope for UTUC specific or large cancer registries to become CQR if they were to feedback to participating centres on a scheduled, routine basis. Disease specific CQR are more resource intensive, however, may attract improved participation given the value of structured reporting and quality improvement processes.</p><p>Whilst RCTs remain the gold-standard methodology for treatment comparison, in recent years the registry-based RCT has been utilised to efficiently analyse and follow-up patients in non-urological areas (<xref rid="r62" ref-type="bibr">62</xref>). Registry based RCT&#8217;s embed elements of the RCT, such as randomisation and other data collection into the registry. The registry then collects data as part of routine care. Such data is then utilised as trial data that allows for analysis. This model lends itself particularly well to comparative effectiveness research such as comparison of outcomes of interventions that are potentially equivalent including nephroureterectomy <italic toggle="yes">vs.</italic> endoscopic management of low-risk tumours. Such analysis requires registries that are well planned, executed and maintained, however has the ability to retain the strengths of an RCT while avoiding the high failure rates, significant costs and lack of external validity (<xref rid="r63" ref-type="bibr">63</xref>). This may be an especially attractive methodology for a rare cancer such as UTUC with its significant recruiting difficulties.</p></sec><sec sec-type="conclusions"><title>Conclusions</title><p>The utilisation of registry-based data in the UTUC literature has increased exponentially over the 20-year review period. Whilst utilisation of large, generalised cancer registries accounts for the majority of the literature in UTUC there are exciting, large UTUC specific registries that will report in the coming years and are likely to contribute more granular, generalisable data for the diagnosis and treatment of UTUC. The ability to provide feedback and benchmarking to clinicians to improve safety and quality should be a consideration in future registry formation as should registry based RCT&#8217;s.</p></sec><sec sec-type="supplementary-material"><title>Supplementary</title><supplementary-material position="float" content-type="local-data" orientation="portrait"><p>The article&#8217;s supplementary files as</p></supplementary-material><supplementary-material position="anchor" id="su1" content-type="local-data" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="tau-12-03-497-rc.pdf" id="d64e869" position="anchor" orientation="portrait"><object-id pub-id-type="doi">10.21037/tau-22-641</object-id></media><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="tau-12-03-497-coif.pdf" id="d64e872" position="anchor" orientation="portrait"><object-id pub-id-type="doi">10.21037/tau-22-641</object-id></media></supplementary-material></sec></body><back><ack><title>Acknowledgments</title><p><italic toggle="yes">Funding: </italic>None.</p></ack><fn-group><fn id="fn1"><p><italic toggle="yes">Reporting Checklist: </italic>The authors have completed the Narrative Review reporting checklist. Available at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://tau.amegroups.com/article/view/10.21037/tau-22-641/rc" ext-link-type="uri">https://tau.amegroups.com/article/view/10.21037/tau-22-641/rc</ext-link></p></fn><fn fn-type="COI-statement"><p><italic toggle="yes">Conflicts of Interest:</italic> All authors have completed the ICMJE uniform disclosure form (available at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://tau.amegroups.com/article/view/10.21037/tau-22-641/coif" ext-link-type="uri">https://tau.amegroups.com/article/view/10.21037/tau-22-641/coif</ext-link>). SS serves as an unpaid editorial board member of <italic toggle="yes">Translational Andrology and Urology </italic>from December 2020 to November 2024. SS reports that he is an honorary board member of the Australia New Zealand Urogenital and Prostate Cancer Trials Group. IDD reports being on the steering committee for IMvigor130, APAC GU Advisory board and director of the Australia New Zealand Urogenital and Prostate Cancer Trials Group. IDD is supported in part by an NHMRC Investigator Grant (No. 2016274). The other authors have no conflicts of interest to declare.</p></fn></fn-group><notes><p content-type="note added in proof"><italic toggle="yes">Ethical Statement: </italic>The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.</p></notes><ref-list><title>References</title><ref id="r1"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ouzzane</surname><given-names>A</given-names></name><name name-style="western"><surname>Roupr&#234;t</surname><given-names>M</given-names></name><name name-style="western"><surname>Leon</surname><given-names>P</given-names></name><etal/></person-group><article-title>Epidemiology and risk factors of upper urinary tract tumors: literature review for the yearly scientific report of the French National Association of Urology.</article-title><source>Prog Urol</source><year>2014</year>;<volume>24</volume>:<fpage>966</fpage>-<lpage>76</lpage>. <pub-id pub-id-type="doi">10.1016/j.purol.2014.06.012</pub-id><pub-id pub-id-type="pmid">25158329</pub-id></mixed-citation></ref><ref id="r2"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alm&#229;s</surname><given-names>B</given-names></name><name name-style="western"><surname>Halvorsen</surname><given-names>OJ</given-names></name><name name-style="western"><surname>Johannesen</surname><given-names>TB</given-names></name><etal/></person-group><article-title>Higher than expected and significantly increasing incidence of upper tract urothelial carcinoma. A population based study.</article-title><source>World J Urol</source><year>2021</year>;<volume>39</volume>:<fpage>3385</fpage>-<lpage>91</lpage>. <pub-id pub-id-type="doi">10.1007/s00345-020-03576-3</pub-id><pub-id pub-id-type="pmid">33420812</pub-id><pub-id pub-id-type="pmcid">PMC8510951</pub-id></mixed-citation></ref><ref id="r3"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Soualhi</surname><given-names>A</given-names></name><name name-style="western"><surname>Rammant</surname><given-names>E</given-names></name><name name-style="western"><surname>George</surname><given-names>G</given-names></name><etal/></person-group><article-title>The incidence and prevalence of upper tract urothelial carcinoma: a systematic review.</article-title><source>BMC Urol</source><year>2021</year>;<volume>21</volume>:<fpage>110</fpage>. <pub-id pub-id-type="doi">10.1186/s12894-021-00876-7</pub-id><pub-id pub-id-type="pmid">34404373</pub-id><pub-id pub-id-type="pmcid">PMC8369798</pub-id></mixed-citation></ref><ref id="r4"><label>4</label><mixed-citation publication-type="other">School of Public Health and Preventative Medicine, Monash University. Registry Science Handbook. 2013.</mixed-citation></ref><ref id="r5"><label>5</label><mixed-citation publication-type="other">Gliklich RE, Dreyer NA, Leavy MB. editors. Registries for Evaluating Patient Outcomes: A User's Guide. Washington, DC, USA: United States Government Printing Office, 2014.</mixed-citation></ref><ref id="r6"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hameed</surname><given-names>BMZ</given-names></name></person-group>, S Dhavileswarapu AVL, Naik N, et al. <article-title>Big Data Analytics in urology: the story so far and the road ahead.</article-title><source>Ther Adv Urol</source><year>2021</year>;<volume>13</volume>:<elocation-id>1756287221998134</elocation-id>. <pub-id pub-id-type="doi">10.1177/1756287221998134</pub-id><pub-id pub-id-type="pmid">33747134</pub-id><pub-id pub-id-type="pmcid">PMC7940776</pub-id></mixed-citation></ref><ref id="r7"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tyson</surname><given-names>MD</given-names></name><name name-style="western"><surname>Barocas</surname><given-names>DA</given-names></name></person-group>. <article-title>Improving quality through clinical registries in urology.</article-title><source>Curr Opin Urol</source><year>2017</year>;<volume>27</volume>:<fpage>375</fpage>-<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1097/MOU.0000000000000406</pub-id><pub-id pub-id-type="pmid">28441270</pub-id><pub-id pub-id-type="pmcid">PMC5567830</pub-id></mixed-citation></ref><ref id="r8"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mauch</surname><given-names>H</given-names></name><name name-style="western"><surname>Kaur</surname><given-names>J</given-names></name><name name-style="western"><surname>Irwin</surname><given-names>C</given-names></name><etal/></person-group><article-title>Design, implementation, and management of an international medical device registry.</article-title><source>Trials</source><year>2021</year>;<volume>22</volume>:<fpage>845</fpage>. <pub-id pub-id-type="doi">10.1186/s13063-021-05821-5</pub-id><pub-id pub-id-type="pmid">34823566</pub-id><pub-id pub-id-type="pmcid">PMC8613936</pub-id></mixed-citation></ref><ref id="r9"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ahern</surname><given-names>S</given-names></name><name name-style="western"><surname>Evans</surname><given-names>SM</given-names></name><name name-style="western"><surname>Hopper</surname><given-names>I</given-names></name><etal/></person-group><article-title>Clinical quality registries for clinician-level reporting: strengths and limitations.</article-title><source>Med J Aust</source><year>2018</year>;<volume>208</volume>:<fpage>323</fpage>. <pub-id pub-id-type="doi">10.5694/mja17.00644</pub-id><pub-id pub-id-type="pmid">29642822</pub-id></mixed-citation></ref><ref id="r10"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hoque</surname><given-names>DME</given-names></name><name name-style="western"><surname>Kumari</surname><given-names>V</given-names></name><name name-style="western"><surname>Hoque</surname><given-names>M</given-names></name><etal/></person-group><article-title>Impact of clinical registries on quality of patient care and clinical outcomes: A systematic review.</article-title><source>PLoS One</source><year>2017</year>;<volume>12</volume>:<elocation-id>e0183667</elocation-id>. <pub-id pub-id-type="doi">10.1371/journal.pone.0183667</pub-id><pub-id pub-id-type="pmid">28886607</pub-id><pub-id pub-id-type="pmcid">PMC5591016</pub-id></mixed-citation></ref><ref id="r11"><label>11</label><mixed-citation publication-type="webpage">National Cancer Institute. SEER Acknowledgment of Treatment Data Limitations. 2022. Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://seer.cancer.gov/data-software/documentation/seerstat/nov2021/treatment-limitations-nov2021.html#:~:text=Three%20main%20limitations%20affect%20recommended,interpretation%20of%20sequence%20data%20variables" ext-link-type="uri">https://seer.cancer.gov/data-software/documentation/seerstat/nov2021/treatment-limitations-nov2021.html#:~:text=Three%20main%20limitations%20affect%20recommended,interpretation%20of%20sequence%20data%20variables</ext-link></mixed-citation></ref><ref id="r12"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Scosyrev</surname><given-names>E</given-names></name><name name-style="western"><surname>Messing</surname><given-names>J</given-names></name><name name-style="western"><surname>Noyes</surname><given-names>K</given-names></name><etal/></person-group><article-title>Surveillance Epidemiology and End Results (SEER) program and population-based research in urologic oncology: an overview.</article-title><source>Urol Oncol</source><year>2012</year>;<volume>30</volume>:<fpage>126</fpage>-<lpage>32</lpage>. <pub-id pub-id-type="doi">10.1016/j.urolonc.2009.11.005</pub-id><pub-id pub-id-type="pmid">20363162</pub-id></mixed-citation></ref><ref id="r13"><label>13</label><mixed-citation publication-type="webpage">American College of Surgeons. National Cancer Database. 2022. Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.facs.org/quality-programs/cancer-programs/national-cancer-database/" ext-link-type="uri">https://www.facs.org/quality-programs/cancer-programs/national-cancer-database/</ext-link></mixed-citation></ref><ref id="r14"><label>14</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Boffa</surname><given-names>DJ</given-names></name><name name-style="western"><surname>Rosen</surname><given-names>JE</given-names></name><name name-style="western"><surname>Mallin</surname><given-names>K</given-names></name><etal/></person-group><article-title>Using the National Cancer Database for Outcomes Research: A Review.</article-title><source>JAMA Oncol</source><year>2017</year>;<volume>3</volume>:<fpage>1722</fpage>-<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1001/jamaoncol.2016.6905</pub-id><pub-id pub-id-type="pmid">28241198</pub-id></mixed-citation></ref><ref id="r15"><label>15</label><mixed-citation publication-type="webpage">American College of Surgeons. National Surgical Quality Improvement Program. 2022. Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.facs.org/quality-programs/data-and-registries/acs-nsqip/" ext-link-type="uri">https://www.facs.org/quality-programs/data-and-registries/acs-nsqip/</ext-link></mixed-citation></ref><ref id="r16"><label>16</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hanske</surname><given-names>J</given-names></name><name name-style="western"><surname>Sanchez</surname><given-names>A</given-names></name><name name-style="western"><surname>Schmid</surname><given-names>M</given-names></name><etal/></person-group><article-title>A Comparison of 30-Day Perioperative Outcomes in Open Versus Minimally Invasive Nephroureterectomy for Upper Tract Urothelial Carcinoma: Analysis of 896 Patients from the American College of Surgeons-National Surgical Quality Improvement Program Database.</article-title><source>J Endourol</source><year>2015</year>;<volume>29</volume>:<fpage>1052</fpage>-<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1089/end.2015.0137</pub-id><pub-id pub-id-type="pmid">25891843</pub-id></mixed-citation></ref><ref id="r17"><label>17</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Soodana-Prakash</surname><given-names>N</given-names></name><name name-style="western"><surname>Balise</surname><given-names>R</given-names></name><name name-style="western"><surname>Nahar</surname><given-names>B</given-names></name><etal/></person-group><article-title>Perioperative outcomes and complication predictors associated with open and minimally invasive nephroureterectomy.</article-title><source>Can J Urol</source><year>2018</year>;<volume>25</volume>:<fpage>9395</fpage>-<lpage>400</lpage>.<pub-id pub-id-type="pmid">30125518</pub-id></mixed-citation></ref><ref id="r18"><label>18</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Geynisman</surname><given-names>DM</given-names></name><name name-style="western"><surname>Broughton</surname><given-names>E</given-names></name><name name-style="western"><surname>Hao</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Real-world treatment patterns and clinical outcomes among patients with advanced urothelial carcinoma in the United States.</article-title><source>Urol Oncol</source><year>2022</year>;<volume>40</volume>:<fpage>195.e1</fpage>-<lpage>195.e11</lpage>. <pub-id pub-id-type="doi">10.1016/j.urolonc.2021.11.014</pub-id><pub-id pub-id-type="pmid">34906410</pub-id></mixed-citation></ref><ref id="r19"><label>19</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tinay</surname><given-names>I</given-names></name><name name-style="western"><surname>Gelpi-Hammerschmidt</surname><given-names>F</given-names></name><name name-style="western"><surname>Leow</surname><given-names>JJ</given-names></name><etal/></person-group><article-title>Trends in utilisation, perioperative outcomes, and costs of nephroureterectomies in the management of upper tract urothelial carcinoma: a 10-year population-based analysis.</article-title><source>BJU Int</source><year>2016</year>;<volume>117</volume>:<fpage>954</fpage>-<lpage>60</lpage>. <pub-id pub-id-type="doi">10.1111/bju.13375</pub-id><pub-id pub-id-type="pmid">26573216</pub-id></mixed-citation></ref><ref id="r20"><label>20</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Deuker</surname><given-names>M</given-names></name><name name-style="western"><surname>Rosiello</surname><given-names>G</given-names></name><name name-style="western"><surname>Stolzenbach</surname><given-names>LF</given-names></name><etal/></person-group><article-title>Sex- and Age-Related Differences in the Distribution of Metastases in Patients With Upper Urinary Tract Urothelial Carcinoma.</article-title><source>J Natl Compr Canc Netw</source><year>2021</year>;<volume>19</volume>:<fpage>534</fpage>-<lpage>40</lpage>. <pub-id pub-id-type="doi">10.6004/jnccn.2020.7637</pub-id><pub-id pub-id-type="pmid">33571954</pub-id></mixed-citation></ref><ref id="r21"><label>21</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Azawi</surname><given-names>NH</given-names></name><name name-style="western"><surname>N&#230;raa</surname><given-names>SH</given-names></name><name name-style="western"><surname>Subhi</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Oncological outcomes of radical nephroureterectomy for upper urinary tract urothelial neoplasia in Denmark.</article-title><source>Scand J Urol</source><year>2020</year>;<volume>54</volume>:<fpage>58</fpage>-<lpage>64</lpage>. <pub-id pub-id-type="doi">10.1080/21681805.2019.1710562</pub-id><pub-id pub-id-type="pmid">31942812</pub-id></mixed-citation></ref><ref id="r22"><label>22</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Potteg&#229;rd</surname><given-names>A</given-names></name><name name-style="western"><surname>Hallas</surname><given-names>J</given-names></name><name name-style="western"><surname>Jensen</surname><given-names>BL</given-names></name><etal/></person-group><article-title>Long-Term Lithium Use and Risk of Renal and Upper Urinary Tract Cancers.</article-title><source>J Am Soc Nephrol</source><year>2016</year>;<volume>27</volume>:<fpage>249</fpage>-<lpage>55</lpage>. <pub-id pub-id-type="doi">10.1681/ASN.2015010061</pub-id><pub-id pub-id-type="pmid">25941353</pub-id><pub-id pub-id-type="pmcid">PMC4696582</pub-id></mixed-citation></ref><ref id="r23"><label>23</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bj&#246;rnsson</surname><given-names>O</given-names></name><name name-style="western"><surname>J&#243;nsson</surname><given-names>E</given-names></name><name name-style="western"><surname>Gu&#240;mundsson</surname><given-names>EO</given-names></name><etal/></person-group><article-title>Operative management in patients with upper tract urothelial carcinoma in Iceland: a population-based study.</article-title><source>Scand J Urol</source><year>2021</year>;<volume>55</volume>:<fpage>197</fpage>-<lpage>202</lpage>. <pub-id pub-id-type="doi">10.1080/21681805.2021.1916073</pub-id><pub-id pub-id-type="pmid">33913379</pub-id></mixed-citation></ref><ref id="r24"><label>24</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>van Doeveren</surname><given-names>T</given-names></name><name name-style="western"><surname>van der Mark</surname><given-names>M</given-names></name><name name-style="western"><surname>van Leeuwen</surname><given-names>PJ</given-names></name><etal/></person-group><article-title>Rising incidence rates and unaltered survival rates for primary upper urinary tract urothelial carcinoma: a Dutch population-based study from 1993 to 2017.</article-title><source>BJU Int</source><year>2021</year>;<volume>128</volume>:<fpage>343</fpage>-<lpage>51</lpage>. <pub-id pub-id-type="doi">10.1111/bju.15389</pub-id><pub-id pub-id-type="pmid">33690922</pub-id><pub-id pub-id-type="pmcid">PMC8453942</pub-id></mixed-citation></ref><ref id="r25"><label>25</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fernandez Aparicio</surname><given-names>T</given-names></name><name name-style="western"><surname>Galan Llopis</surname><given-names>JA</given-names></name><name name-style="western"><surname>Cansino Alcaide</surname><given-names>R</given-names></name><etal/></person-group><article-title>Incidence of upper tract urothelial carcinoma in Spain.</article-title><source>Actas Urol Esp</source><comment>(Engl Ed)</comment><year>2020</year>;<volume>44</volume>:<fpage>512</fpage>-<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1016/j.acuro.2020.03.007</pub-id><pub-id pub-id-type="pmid">32622540</pub-id></mixed-citation></ref><ref id="r26"><label>26</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Medunjanin</surname><given-names>D</given-names></name><name name-style="western"><surname>Sonicki</surname><given-names>Z</given-names></name><name name-style="western"><surname>Vena</surname><given-names>JE</given-names></name><etal/></person-group><article-title>Geographic distribution and risk of upper urothelial carcinomas in Croatia, 2001-2011.</article-title><source>BMC Cancer</source><year>2019</year>;<volume>19</volume>:<fpage>950</fpage>. <pub-id pub-id-type="doi">10.1186/s12885-019-6160-9</pub-id><pub-id pub-id-type="pmid">31615453</pub-id><pub-id pub-id-type="pmcid">PMC6792263</pub-id></mixed-citation></ref><ref id="r27"><label>27</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Eylert</surname><given-names>MF</given-names></name><name name-style="western"><surname>Hounsome</surname><given-names>L</given-names></name><name name-style="western"><surname>Verne</surname><given-names>J</given-names></name><etal/></person-group><article-title>Prognosis is deteriorating for upper tract urothelial cancer: data for England 1985-2010.</article-title><source>BJU Int</source><year>2013</year>;<volume>112</volume>:<fpage>E107</fpage>-<lpage>13</lpage>. <pub-id pub-id-type="doi">10.1111/bju.12025</pub-id><pub-id pub-id-type="pmid">23470094</pub-id></mixed-citation></ref><ref id="r28"><label>28</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Visser</surname><given-names>O</given-names></name><name name-style="western"><surname>Adolfsson</surname><given-names>J</given-names></name><name name-style="western"><surname>Rossi</surname><given-names>S</given-names></name><etal/></person-group><article-title>Incidence and survival of rare urogenital cancers in Europe.</article-title><source>Eur J Cancer</source><year>2012</year>;<volume>48</volume>:<fpage>456</fpage>-<lpage>64</lpage>. <pub-id pub-id-type="doi">10.1016/j.ejca.2011.10.031</pub-id><pub-id pub-id-type="pmid">22119351</pub-id></mixed-citation></ref><ref id="r29"><label>29</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nagumo</surname><given-names>Y</given-names></name><name name-style="western"><surname>Kawai</surname><given-names>K</given-names></name><name name-style="western"><surname>Kojima</surname><given-names>T</given-names></name><etal/></person-group><article-title>Prognostic impact of non-urothelial carcinoma of the upper urinary tract: Analysis of hospital-based cancer registry data in Japan.</article-title><source>Int J Urol</source><year>2021</year>;<volume>28</volume>:<fpage>54</fpage>-<lpage>60</lpage>. <pub-id pub-id-type="doi">10.1111/iju.14393</pub-id><pub-id pub-id-type="pmid">33167076</pub-id></mixed-citation></ref><ref id="r30"><label>30</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shiga</surname><given-names>M</given-names></name><name name-style="western"><surname>Nagumo</surname><given-names>Y</given-names></name><name name-style="western"><surname>Chihara</surname><given-names>I</given-names></name><etal/></person-group><article-title>Discrepancy between clinical and pathological T stages in upper urinary tract urothelial carcinoma: Analysis of the Hospital-Based Cancer Registry data in Japan.</article-title><source>Int J Urol</source><year>2021</year>;<volume>28</volume>:<fpage>814</fpage>-<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1111/iju.14583</pub-id><pub-id pub-id-type="pmid">34013614</pub-id></mixed-citation></ref><ref id="r31"><label>31</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>J</given-names></name><name name-style="western"><surname>Chen</surname><given-names>S</given-names></name><name name-style="western"><surname>Wu</surname><given-names>X</given-names></name><etal/></person-group><article-title>Trends of incidence and prognosis of upper tract urothelial carcinoma.</article-title><source>Bosn J Basic Med Sci</source><year>2021</year>;<volume>21</volume>:<fpage>607</fpage>-<lpage>19</lpage>.<pub-id pub-id-type="pmid">33357210</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.17305/bjbms.2020.5345</pub-id><pub-id pub-id-type="pmcid">PMC8381214</pub-id></mixed-citation></ref><ref id="r32"><label>32</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Woodford</surname><given-names>R</given-names></name><name name-style="western"><surname>Ranasinghe</surname><given-names>W</given-names></name><name name-style="western"><surname>Aw</surname><given-names>HC</given-names></name><etal/></person-group><article-title>Trends in incidence and survival for upper tract urothelial cancer (UTUC) in the state of Victoria--Australia.</article-title><source>BJU Int</source><year>2016</year>;<volume>117</volume><issue>Suppl 4</issue>:<fpage>45</fpage>-<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1111/bju.13232</pub-id><pub-id pub-id-type="pmid">26486693</pub-id></mixed-citation></ref><ref id="r33"><label>33</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Connolly</surname><given-names>SS</given-names></name><name name-style="western"><surname>Rochester</surname><given-names>MA</given-names></name></person-group>; . <article-title>Nephroureterectomy surgery in the UK in 2012: British Association of Urological Surgeons (BAUS) Registry data.</article-title><source>BJU Int</source><year>2015</year>;<volume>116</volume>:<fpage>780</fpage>-<lpage>90</lpage>. <pub-id pub-id-type="doi">10.1111/bju.12827</pub-id><pub-id pub-id-type="pmid">24906188</pub-id></mixed-citation></ref><ref id="r34"><label>34</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bamias</surname><given-names>A</given-names></name><name name-style="western"><surname>Tzannis</surname><given-names>K</given-names></name><name name-style="western"><surname>Harshman</surname><given-names>LC</given-names></name><etal/></person-group><article-title>Impact of contemporary patterns of chemotherapy utilization on survival in patients with advanced cancer of the urinary tract: a Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC).</article-title><source>Ann Oncol</source><year>2018</year>;<volume>29</volume>:<fpage>361</fpage>-<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1093/annonc/mdx692</pub-id><pub-id pub-id-type="pmid">29077785</pub-id><pub-id pub-id-type="pmcid">PMC7360142</pub-id></mixed-citation></ref><ref id="r35"><label>35</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Necchi</surname><given-names>A</given-names></name><name name-style="western"><surname>Sonpavde</surname><given-names>G</given-names></name><name name-style="western"><surname>Lo Vullo</surname><given-names>S</given-names></name><etal/></person-group><article-title>Nomogram-based Prediction of Overall Survival in Patients with Metastatic Urothelial Carcinoma Receiving First-line Platinum-based Chemotherapy: Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC).</article-title><source>Eur Urol</source><year>2017</year>;<volume>71</volume>:<fpage>281</fpage>-<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1016/j.eururo.2016.09.042</pub-id><pub-id pub-id-type="pmid">27726966</pub-id><pub-id pub-id-type="pmcid">PMC5576985</pub-id></mixed-citation></ref><ref id="r36"><label>36</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bamias</surname><given-names>A</given-names></name><name name-style="western"><surname>Tzannis</surname><given-names>K</given-names></name><name name-style="western"><surname>Liontos</surname><given-names>M</given-names></name><etal/></person-group><article-title>Adherence to cisplatin-based regimens prescription in "fit" patients fulfilling platinum eligibility criteria. Impact on outcomes: a retrospective international study of invasive/advanced cancer of the urothelium (RISC) analysis.</article-title><source>Ann Oncol</source><year>2016</year>;<volume>27</volume>. doi: .<pub-id pub-id-type="doi">10.1093/annonc/mdw373.27</pub-id></mixed-citation></ref><ref id="r37"><label>37</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bamias</surname><given-names>A</given-names></name><name name-style="western"><surname>Tzannis</surname><given-names>K</given-names></name><name name-style="western"><surname>Liontos</surname><given-names>M</given-names></name><etal/></person-group><article-title>Patterns of chemotherapy utilization in metastatic urothelial cancer (mUC): analysis from the retrospective international study of invasive/advanced cancer of the urothelium (RISC) database.</article-title><source>Ann Oncol</source><year>2016</year>;<volume>27</volume>. doi: .<pub-id pub-id-type="doi">10.1093/annonc/mdw373.26</pub-id></mixed-citation></ref><ref id="r38"><label>38</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hara</surname><given-names>T</given-names></name><name name-style="western"><surname>Fujimoto</surname><given-names>H</given-names></name><name name-style="western"><surname>Kondo</surname><given-names>T</given-names></name><etal/></person-group><article-title>Active heavy cigarette smoking is associated with poor survival in Japanese patients with advanced renal cell carcinoma: sub-analysis of the multi-institutional national database of the Japanese Urological Association.</article-title><source>Jpn J Clin Oncol</source><year>2017</year>;<volume>47</volume>:<fpage>1162</fpage>-<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1093/jjco/hyx129</pub-id><pub-id pub-id-type="pmid">29121328</pub-id></mixed-citation></ref><ref id="r39"><label>39</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hara</surname><given-names>T</given-names></name><name name-style="western"><surname>Fujimoto</surname><given-names>H</given-names></name><name name-style="western"><surname>Sakura</surname><given-names>M</given-names></name><etal/></person-group><article-title>Prognostic factors of recurrent disease in upper urinary tract urothelial cancer after radical nephroureterectomy: Subanalysis of the multi-institutional national database of the Japanese Urological Association.</article-title><source>Int J Urol</source><year>2015</year>;<volume>22</volume>:<fpage>1013</fpage>-<lpage>20</lpage>. <pub-id pub-id-type="doi">10.1111/iju.12884</pub-id><pub-id pub-id-type="pmid">26242807</pub-id></mixed-citation></ref><ref id="r40"><label>40</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Miyazaki</surname><given-names>J</given-names></name><name name-style="western"><surname>Nishiyama</surname><given-names>H</given-names></name><name name-style="western"><surname>Fujimoto</surname><given-names>H</given-names></name><etal/></person-group><article-title>Impact of smoking on the age at diagnosis of upper tract urothelial carcinoma: Subanalysis of the Japanese Urological Association multi-institutional national database.</article-title><source>Int J Urol</source><year>2015</year>;<volume>22</volume>:<fpage>1023</fpage>-<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1111/iju.12886</pub-id><pub-id pub-id-type="pmid">26238570</pub-id></mixed-citation></ref><ref id="r41"><label>41</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Miyazaki</surname><given-names>J</given-names></name><name name-style="western"><surname>Nishiyama</surname><given-names>H</given-names></name><name name-style="western"><surname>Fujimoto</surname><given-names>H</given-names></name><etal/></person-group><article-title>Laparoscopic Versus Open Nephroureterectomy in Muscle-Invasive Upper Tract Urothelial Carcinoma: Subanalysis of the Multi-Institutional National Database of the Japanese Urological Association.</article-title><source>J Endourol</source><year>2016</year>;<volume>30</volume>:<fpage>520</fpage>-<lpage>5</lpage>. <pub-id pub-id-type="doi">10.1089/end.2015.0757</pub-id><pub-id pub-id-type="pmid">26669358</pub-id></mixed-citation></ref><ref id="r42"><label>42</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ku</surname><given-names>JH</given-names></name><name name-style="western"><surname>Moon</surname><given-names>KC</given-names></name><name name-style="western"><surname>Jung</surname><given-names>JH</given-names></name><etal/></person-group><article-title>External validation of an online nomogram in patients undergoing radical nephroureterectomy for upper urinary tract urothelial carcinoma.</article-title><source>Br J Cancer</source><year>2013</year>;<volume>109</volume>:<fpage>1130</fpage>-<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1038/bjc.2013.462</pub-id><pub-id pub-id-type="pmid">23949152</pub-id><pub-id pub-id-type="pmcid">PMC3778306</pub-id></mixed-citation></ref><ref id="r43"><label>43</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pignot</surname><given-names>G</given-names></name><name name-style="western"><surname>Colin</surname><given-names>P</given-names></name><name name-style="western"><surname>Zerbib</surname><given-names>M</given-names></name><etal/></person-group><article-title>Influence of previous or synchronous bladder cancer on oncologic outcomes after radical nephroureterectomy for upper urinary tract urothelial carcinoma.</article-title><source>Urol Oncol</source><year>2014</year>;<volume>32</volume>:<fpage>23.e1</fpage>-<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1016/j.urolonc.2012.08.010</pub-id><pub-id pub-id-type="pmid">23403206</pub-id></mixed-citation></ref><ref id="r44"><label>44</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Colin</surname><given-names>P</given-names></name><name name-style="western"><surname>Ouzzane</surname><given-names>A</given-names></name><name name-style="western"><surname>Pignot</surname><given-names>G</given-names></name><etal/></person-group><article-title>Comparison of oncological outcomes after segmental ureterectomy or radical nephroureterectomy in urothelial carcinomas of the upper urinary tract: results from a large French multicentre study.</article-title><source>BJU Int</source><year>2012</year>;<volume>110</volume>:<fpage>1134</fpage>-<lpage>41</lpage>. <pub-id pub-id-type="doi">10.1111/j.1464-410X.2012.10960.x</pub-id><pub-id pub-id-type="pmid">22394612</pub-id></mixed-citation></ref><ref id="r45"><label>45</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Audenet</surname><given-names>F</given-names></name><name name-style="western"><surname>Colin</surname><given-names>P</given-names></name><name name-style="western"><surname>Yates</surname><given-names>DR</given-names></name><etal/></person-group><article-title>A proportion of hereditary upper urinary tract urothelial carcinomas are misclassified as sporadic according to a multi-institutional database analysis: proposal of patient-specific risk identification tool.</article-title><source>BJU Int</source><year>2012</year>;<volume>110</volume>:<fpage>E583</fpage>-<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1111/j.1464-410X.2012.11298.x</pub-id><pub-id pub-id-type="pmid">22703159</pub-id></mixed-citation></ref><ref id="r46"><label>46</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Berod</surname><given-names>AA</given-names></name><name name-style="western"><surname>Colin</surname><given-names>P</given-names></name><name name-style="western"><surname>Yates</surname><given-names>DR</given-names></name><etal/></person-group><article-title>The role of American Society of Anesthesiologists scores in predicting urothelial carcinoma of the upper urinary tract outcome after radical nephroureterectomy: results from a national multi-institutional collaborative study.</article-title><source>BJU Int</source><year>2012</year>;<volume>110</volume>:<fpage>E1035</fpage>-<lpage>40</lpage>. <pub-id pub-id-type="doi">10.1111/j.1464-410X.2012.11195.x</pub-id><pub-id pub-id-type="pmid">22568669</pub-id></mixed-citation></ref><ref id="r47"><label>47</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vassilakopoulou</surname><given-names>M</given-names></name><name name-style="western"><surname>de la Motte Rouge</surname><given-names>T</given-names></name><name name-style="western"><surname>Colin</surname><given-names>P</given-names></name><etal/></person-group><article-title>Outcomes after adjuvant chemotherapy in the treatment of high-risk urothelial carcinoma of the upper urinary tract (UUT-UC): results from a large multicenter collaborative study.</article-title><source>Cancer</source><year>2011</year>;<volume>117</volume>:<fpage>5500</fpage>-<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1002/cncr.26172</pub-id><pub-id pub-id-type="pmid">21638278</pub-id></mixed-citation></ref><ref id="r48"><label>48</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>YT</given-names></name><name name-style="western"><surname>Yu</surname><given-names>CC</given-names></name><name name-style="western"><surname>Yeh</surname><given-names>HC</given-names></name><etal/></person-group><article-title>Endoscopic management versus radical nephroureterectomy for localized upper tract urothelial carcinoma in a high endemic region.</article-title><source>Sci Rep</source><year>2021</year>;<volume>11</volume>:<fpage>4040</fpage>. <pub-id pub-id-type="doi">10.1038/s41598-021-83495-4</pub-id><pub-id pub-id-type="pmid">33597574</pub-id><pub-id pub-id-type="pmcid">PMC7889610</pub-id></mixed-citation></ref><ref id="r49"><label>49</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jeldres</surname><given-names>C</given-names></name><name name-style="western"><surname>Lughezzani</surname><given-names>G</given-names></name><name name-style="western"><surname>Sun</surname><given-names>M</given-names></name><etal/></person-group><article-title>Segmental ureterectomy can safely be performed in patients with transitional cell carcinoma of the ureter.</article-title><source>J Urol</source><year>2010</year>;<volume>183</volume>:<fpage>1324</fpage>-<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1016/j.juro.2009.12.018</pub-id><pub-id pub-id-type="pmid">20171666</pub-id></mixed-citation></ref><ref id="r50"><label>50</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>IA</given-names></name><name name-style="western"><surname>Chang</surname><given-names>CH</given-names></name><name name-style="western"><surname>Huang</surname><given-names>CP</given-names></name><etal/></person-group><article-title>Factors Predicting Oncological Outcomes of Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma in Taiwan.</article-title><source>Front Oncol</source><year>2022</year>;<volume>11</volume>:<elocation-id>766576</elocation-id>. <pub-id pub-id-type="doi">10.3389/fonc.2021.766576</pub-id><pub-id pub-id-type="pmid">35096575</pub-id><pub-id pub-id-type="pmcid">PMC8793058</pub-id></mixed-citation></ref><ref id="r51"><label>51</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Baard</surname><given-names>J</given-names></name><name name-style="western"><surname>Cormio</surname><given-names>L</given-names></name><name name-style="western"><surname>Cavadas</surname><given-names>V</given-names></name><etal/></person-group><article-title>Contemporary patterns of presentation, diagnostics and management of upper tract urothelial cancer in 101 centres: the Clinical Research Office of the Endourological Society Global upper tract urothelial carcinoma registry.</article-title><source>Curr Opin Urol</source><year>2021</year>;<volume>31</volume>:<fpage>354</fpage>-<lpage>62</lpage>. <pub-id pub-id-type="doi">10.1097/MOU.0000000000000899</pub-id><pub-id pub-id-type="pmid">34009177</pub-id></mixed-citation></ref><ref id="r52"><label>52</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Soria</surname><given-names>F</given-names></name><name name-style="western"><surname>Laguna</surname><given-names>MP</given-names></name><name name-style="western"><surname>Roupret</surname><given-names>M</given-names></name><etal/></person-group><article-title>Flexible fibre optic vs digital ureteroscopy and enhanced vs unenhanced imaging for diagnosis and treatment of upper tract urothelial carcinoma (UTUC): results from the Clinical Research Office of the Endourology Society (CROES)-UTUC registry.</article-title><source>BJU Int</source><year>2021</year>;<volume>128</volume>:<fpage>734</fpage>-<lpage>43</lpage>. <pub-id pub-id-type="doi">10.1111/bju.15494</pub-id><pub-id pub-id-type="pmid">34028166</pub-id><pub-id pub-id-type="pmcid">PMC9292011</pub-id></mixed-citation></ref><ref id="r53"><label>53</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Katims</surname><given-names>AB</given-names></name><name name-style="western"><surname>Say</surname><given-names>R</given-names></name><name name-style="western"><surname>Derweesh</surname><given-names>I</given-names></name><etal/></person-group><article-title>Risk Factors for Intravesical Recurrence after Minimally Invasive Nephroureterectomy for Upper Tract Urothelial Cancer (ROBUUST Collaboration).</article-title><source>J Urol</source><year>2021</year>;<volume>206</volume>:<fpage>568</fpage>-<lpage>76</lpage>. <pub-id pub-id-type="doi">10.1097/JU.0000000000001786</pub-id><pub-id pub-id-type="pmid">33881931</pub-id></mixed-citation></ref><ref id="r54"><label>54</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hakimi</surname><given-names>K</given-names></name><name name-style="western"><surname>Carbonara</surname><given-names>U</given-names></name><name name-style="western"><surname>Djaladat</surname><given-names>H</given-names></name><etal/></person-group><article-title>Outcomes of Lymph Node Dissection in Nephroureterectomy in the Treatment of Upper Tract Urothelial Carcinoma: Analysis of the ROBUUST Registry.</article-title><source>J Urol</source><year>2022</year>;<volume>208</volume>:<fpage>268</fpage>-<lpage>76</lpage>. <pub-id pub-id-type="doi">10.1097/JU.0000000000002690</pub-id><pub-id pub-id-type="pmid">35377778</pub-id></mixed-citation></ref><ref id="r55"><label>55</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>Z</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Q</given-names></name><name name-style="western"><surname>Djaladat</surname><given-names>H</given-names></name><etal/></person-group><article-title>A Preoperative Nomogram to Predict Renal Function Insufficiency for Cisplatin-based Adjuvant Chemotherapy Following Minimally Invasive Radical Nephroureterectomy (ROBUUST Collaborative Group).</article-title><source>Eur Urol Focus</source><year>2022</year>;<volume>8</volume>:<fpage>173</fpage>-<lpage>81</lpage>. <pub-id pub-id-type="doi">10.1016/j.euf.2021.01.014</pub-id><pub-id pub-id-type="pmid">33549537</pub-id></mixed-citation></ref><ref id="r56"><label>56</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Almassi</surname><given-names>N</given-names></name><name name-style="western"><surname>Gao</surname><given-names>T</given-names></name><name name-style="western"><surname>Lee</surname><given-names>B</given-names></name><etal/></person-group><article-title>Impact of Neoadjuvant Chemotherapy on Pathologic Response in Patients With Upper Tract Urothelial Carcinoma Undergoing Extirpative Surgery.</article-title><source>Clin Genitourin Cancer</source><year>2018</year>;<volume>16</volume>:<fpage>e1237</fpage>-<lpage>42</lpage>. <pub-id pub-id-type="doi">10.1016/j.clgc.2018.08.003</pub-id><pub-id pub-id-type="pmid">30217764</pub-id></mixed-citation></ref><ref id="r57"><label>57</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Karanatsios</surname><given-names>B</given-names></name><name name-style="western"><surname>Prang</surname><given-names>KH</given-names></name><name name-style="western"><surname>Verbunt</surname><given-names>E</given-names></name><etal/></person-group><article-title>Defining key design elements of registry-based randomised controlled trials: a scoping review.</article-title><source>Trials</source><year>2020</year>;<volume>21</volume>:<fpage>552</fpage>. <pub-id pub-id-type="doi">10.1186/s13063-020-04459-z</pub-id><pub-id pub-id-type="pmid">32571382</pub-id><pub-id pub-id-type="pmcid">PMC7310018</pub-id></mixed-citation></ref><ref id="r58"><label>58</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Prang</surname><given-names>KH</given-names></name><name name-style="western"><surname>Karanatsios</surname><given-names>B</given-names></name><name name-style="western"><surname>Verbunt</surname><given-names>E</given-names></name><etal/></person-group><article-title>Clinical registries data quality attributes to support registry-based randomised controlled trials: A scoping review.</article-title><source>Contemp Clin Trials</source><year>2022</year>;<volume>119</volume>:<elocation-id>106843</elocation-id>. <pub-id pub-id-type="doi">10.1016/j.cct.2022.106843</pub-id><pub-id pub-id-type="pmid">35792338</pub-id></mixed-citation></ref><ref id="r59"><label>59</label><mixed-citation publication-type="webpage">European Network for Health Technology Assessment. Registry Evaluation and Quality Standards Tool (REQueST). 2021. Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.eunethta.eu/request-tool-and-its-vision-paper/" ext-link-type="uri">https://www.eunethta.eu/request-tool-and-its-vision-paper/</ext-link></mixed-citation></ref><ref id="r60"><label>60</label><mixed-citation publication-type="other">Australian Commission on Safety and Quality in Health Care. Framework for Australian clinical quality registries. 2014.</mixed-citation></ref><ref id="r61"><label>61</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>O'Callaghan</surname><given-names>M</given-names></name><name name-style="western"><surname>Papa</surname><given-names>N</given-names></name><name name-style="western"><surname>Pase</surname><given-names>M</given-names></name><etal/></person-group><article-title>Patterns of care for prostate cancer treatment and improving outcomes - are national registries the answer?</article-title><source>BJU Int</source><year>2021</year>;<volume>128</volume><issue>Suppl 1</issue>:<fpage>6</fpage>-<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1111/bju.15366</pub-id><pub-id pub-id-type="pmid">33977631</pub-id></mixed-citation></ref><ref id="r62"><label>62</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>G</given-names></name><name name-style="western"><surname>Sajobi</surname><given-names>TT</given-names></name><name name-style="western"><surname>Menon</surname><given-names>BK</given-names></name><etal/></person-group><article-title>Registry-based randomized controlled trials- what are the advantages, challenges, and areas for future research?</article-title><source>J Clin Epidemiol</source><year>2016</year>;<volume>80</volume>:<fpage>16</fpage>-<lpage>24</lpage>. <pub-id pub-id-type="doi">10.1016/j.jclinepi.2016.08.003</pub-id><pub-id pub-id-type="pmid">27555082</pub-id></mixed-citation></ref><ref id="r63"><label>63</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Foroughi</surname><given-names>S</given-names></name><name name-style="western"><surname>Wong</surname><given-names>HL</given-names></name><name name-style="western"><surname>Gately</surname><given-names>L</given-names></name><etal/></person-group><article-title>Re-inventing the randomized controlled trial in medical oncology: The registry-based trial.</article-title><source>Asia Pac J Clin Oncol</source><year>2018</year>;<volume>14</volume>:<fpage>365</fpage>-<lpage>73</lpage>. <pub-id pub-id-type="doi">10.1111/ajco.12992</pub-id><pub-id pub-id-type="pmid">29947051</pub-id></mixed-citation></ref></ref-list></back></article></pmc-articleset>